BRPI0214840B8 - métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa - Google Patents

métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa

Info

Publication number
BRPI0214840B8
BRPI0214840B8 BRPI0214840A BR0214840A BRPI0214840B8 BR PI0214840 B8 BRPI0214840 B8 BR PI0214840B8 BR PI0214840 A BRPI0214840 A BR PI0214840A BR 0214840 A BR0214840 A BR 0214840A BR PI0214840 B8 BRPI0214840 B8 BR PI0214840B8
Authority
BR
Brazil
Prior art keywords
methods
detecting
mutation
assay
identifying
Prior art date
Application number
BRPI0214840A
Other languages
English (en)
Other versions
BR0214840A (pt
BRPI0214840B1 (pt
Inventor
Futreal Andy
Marshall Chris
Stratton Mike
Malcolm Marais Richard
Wooster Richard
Original Assignee
The Wellcome Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0130796A external-priority patent/GB0130796D0/en
Application filed by The Wellcome Trust filed Critical The Wellcome Trust
Publication of BR0214840A publication Critical patent/BR0214840A/pt
Publication of BRPI0214840B1 publication Critical patent/BRPI0214840B1/pt
Publication of BRPI0214840B8 publication Critical patent/BRPI0214840B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"genes". a invenção se refere a mutações nos produtos de gene b-raf. as mutações descritas são identificadas em tumores humanos de origem natural. essas mutações estão associadas com fenótipos cancerosos e podem ser usadas como uma base para o diagnóstico do câncer, células cancerosas ou uma predisposição ao câncer em indivíduos humanos, e ao desenvolvimento de terapêuticos anti-câncer.
BRPI0214840A 2001-12-21 2002-12-23 métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa BRPI0214840B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0130796A GB0130796D0 (en) 2001-12-21 2001-12-21 Genes
GB0130796.6 2001-12-21
US34468401P 2001-12-24 2001-12-24
US60/344,684 2001-12-24
PCT/GB2002/005891 WO2003056036A2 (en) 2001-12-21 2002-12-23 Genes

Publications (3)

Publication Number Publication Date
BR0214840A BR0214840A (pt) 2004-08-31
BRPI0214840B1 BRPI0214840B1 (pt) 2020-12-08
BRPI0214840B8 true BRPI0214840B8 (pt) 2021-05-25

Family

ID=26246901

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0214840A BRPI0214840B8 (pt) 2001-12-21 2002-12-23 métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa

Country Status (8)

Country Link
US (2) US7947819B2 (pt)
EP (1) EP1456364B1 (pt)
JP (2) JP4643909B2 (pt)
AU (1) AU2002353228B2 (pt)
BR (1) BRPI0214840B8 (pt)
CA (1) CA2471114C (pt)
NZ (1) NZ532780A (pt)
WO (1) WO2003056036A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
CA2526636C (en) 2003-05-20 2012-10-02 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
JP2005013221A (ja) * 2003-06-03 2005-01-20 Keio Gijuku Ｂｒａｆ発現抑制を利用した癌の治療
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
AU2003286447A1 (en) * 2003-10-16 2004-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
US20070020657A1 (en) * 2005-05-20 2007-01-25 Grebe Stefan K Methods for detecting circulating tumor cells
EP2013207B1 (en) 2006-04-26 2012-04-25 Cancer Research Technology Limited Imidazo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
KR101573026B1 (ko) 2007-07-25 2015-11-30 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료에서 이용하기 위한 멀티키나아제 억제제
US20090170925A1 (en) * 2007-10-29 2009-07-02 Eisai R&D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
EP2229391B1 (en) 2007-12-19 2014-08-06 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
EP3075864A1 (en) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
US8728763B2 (en) 2009-08-11 2014-05-20 Response Genetics Methods, primers, probes and kits useful for the detection of BRAF mutations
PL2531502T3 (pl) 2010-02-01 2014-08-29 Cancer Research Tech Ltd 1-(5-tert-Butylo-2-fenylo-2H-pirazol-3-ilo)-3-[2-fluoro-4-(1-metylo-2-okso-2,3-dihydro-1H-imidazo[4,5-b]pirydyn-7-yloksy)-fenylo]-mocznik i związki pokrewne oraz ich zastosowanie w terapii
CA2810931C (en) 2010-09-24 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
CA3156589A1 (en) 2019-11-06 2021-05-14 David M. Kurtz Methods and systems for analyzing nucleic acid molecules
US11783912B2 (en) 2021-05-05 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981731A (en) * 1994-05-31 1999-11-09 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of B-raf gene expression
US6432634B1 (en) * 1996-04-18 2002-08-13 Visible Genetics Inc. Method, apparatus and kits for sequencing of nucleic acids using multiple dyes
GB9623833D0 (en) * 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
DE59802537D1 (de) * 1997-04-15 2002-01-31 Gmd Gmbh Frei programmierbares, universelles parallel-rechnersystem zur durchführung von allgemeinen berechnungen
AU2198999A (en) * 1997-12-22 1999-07-12 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
GB9919226D0 (en) * 1999-08-13 1999-10-20 Medical Res Council Allele detection

Also Published As

Publication number Publication date
JP4643909B2 (ja) 2011-03-02
US20050186584A1 (en) 2005-08-25
JP2006503542A (ja) 2006-02-02
CA2471114A1 (en) 2003-07-10
WO2003056036A3 (en) 2003-12-31
NZ532780A (en) 2006-10-27
EP1456364B1 (en) 2011-03-23
US7947819B2 (en) 2011-05-24
EP1456364A2 (en) 2004-09-15
US8580497B2 (en) 2013-11-12
AU2002353228A1 (en) 2003-07-15
BR0214840A (pt) 2004-08-31
JP2010246545A (ja) 2010-11-04
AU2002353228B2 (en) 2008-09-11
CA2471114C (en) 2012-03-20
BRPI0214840B1 (pt) 2020-12-08
US20110189688A1 (en) 2011-08-04
WO2003056036A2 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
BRPI0214840B8 (pt) métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa
Plimack et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer
Nordlund et al. Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia
Chen et al. Wide spectrum of filaggrin‐null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations
Byun et al. Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue-and individual-specific DNA methylation patterns
EP1597353A4 (en) CIRCULATING TUMOR CELLS (CTC): EARLY EVALUATION OF EVOLUTION TIME, SURVIVAL AND REACTION TO THERAPIES OF METASTASIC CANCER PATIENTS
Lampis et al. The inter-regional distribution of HLA class II haplotypes indicates the suitability of the Sardinian population for case–control association studies in complex diseases
WO2005024603A3 (en) Methods for detecting, diagnosing and treating human renal cell carcinoma
Ono et al. Association of dietary and genetic factors related to one‐carbon metabolism with global methylation level of leukocyte DNA
WO2006060265A3 (en) Methods and systems for prognosis and treatment of solid tumors
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
Jdey et al. Drug-driven synthetic lethality: bypassing tumor cell genetics with a combination of AsiDNA and PARP inhibitors
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
Sanna et al. Tumor genetic heterogeneity analysis of chronic sun‐damaged melanoma
EP1404365A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING, PREVENTING OR REDUCING TUMOR CELL GROWTH IN PATIENTS RESISTANT TO ANTI-NEOPLASTIC EFFECTS OF ANTI-OESTROGEN TREATMENT
WO2007124309A3 (en) Methods for detecting mutations in jak2 nucleic acid
Guney et al. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes
Akula et al. Computational analysis of epidermal growth factor receptor mutations predicts differential drug sensitivity profiles toward kinase inhibitors
ATE264922T1 (de) Verfahren zur erkennung von klonalen populationen von transformierten zellen in einer genomisch heterogenen zellulären probe
Tessitore et al. Expression of phosphatidylethanolamine N-methyltransferase in human hepatocellular carcinomas
Woollard et al. Independent loss of methylthioadenosine phosphorylase (MTAP) in primary cutaneous T-cell lymphoma
Angchaisuksiri et al. Prevalence of the C677T methylenetetra-hydrofolate reductase mutation in Thai patients with deep vein thrombosis
Milingou et al. Focal palmoplantar keratoderma caused by an autosomal dominant inherited mutation in the desmoglein 1 gene
Ogawa Splicing factor mutations in AML
Thita et al. Phenotypic and genotypic characterization of Thai isolates of Plasmodium falciparum after an artemisinin resistance containment project

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 9/12 , C07K 16/40 , C12Q 1/48 , C12Q 1/68

Ipc: C12N 9/12 (2006.01), C07K 16/40 (2006.01), C12Q 1/

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2283 DE 07/10/2014.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 23/12/2022